TG Therapeutics stock moved lower in pre-market trading, down 4.7% to $49.60, shortly after the company released its second-quarter 2026 financials before the market opened. The quarter produced total global revenue of $240.3 million, ahead of the analyst consensus of approximately $228.85 million, and management raised its full-year 2026 global revenue target to about $950 million. The company also nudged up its U.S. net product revenue guidance for Briumvi to a range of $890 million to $905 million.
Even with the tangible top-line beat and stronger guidance, the stock movement appears driven by a classic 'sell the news' reaction. Analysts and investors had already priced in a robust report, leaving little margin for surprise. The market had been expecting 141.2% EPS growth and a 63.5% increase in revenue heading into the release, creating a high bar for the company's results.
Analyst sentiment around the stock remains polarized and continues to influence investor behavior. Bank of America has kept an Underperform rating and a price target of $20, a notably conservative view relative to more bullish firms. By contrast, Jefferies and B. Riley carry substantially higher price targets of $83 and $86, respectively. That wide spread of opinions highlights disagreement over the stock's valuation at its current trading level.
The weakness in TGTX's pre-market session appears to be company-specific rather than a reflection of broader market weakness. Major indexes were trading higher at the time of the report - the S&P 500 up 0.6%, the Dow Jones up 1.0%, and the NASDAQ up 0.3% - indicating the decline was not driven by macroeconomic pressure. Likewise, no material developments from key multiple sclerosis competitors, including Roche and its Ocrevus franchise, were reported that might explain a correlated move in TG Therapeutics' shares.
Taken together, the pre-market selloff underscores a tension between demonstrable commercial momentum for Briumvi and a share price that had already mirrored much of that optimism. The stock remains well above its 52-week low of $25.28, reflecting the run-up investors have assigned to the company in recent months.
Attention now shifts to the company's earnings conference call, scheduled for 8:30 AM ET, where investors will scrutinize management's commentary. Key topics likely to shape sentiment include the path the company outlines toward a roughly $1 billion annualized U.S. revenue run rate and any additional detail surrounding the timeline for subcutaneous Briumvi Phase 3 data expected around year-end. These forward-looking commentaries may determine whether the market views today's pullback as temporary profit-taking or the start of a more sustained reassessment.
Summary
- TG Therapeutics reported Q2 2026 global revenue of $240.3 million, beating the roughly $228.85 million analyst consensus and raising full-year global guidance to about $950 million.
- The company increased U.S. Briumvi net product revenue guidance to $890 million-$905 million.
- Despite the top-line beat and guidance raise, shares fell 4.7% pre-market to $49.60 amid a sell-the-news reaction and elevated market expectations.
What to watch next
- Management commentary on the earnings call at 8:30 AM ET for color on the trajectory toward a roughly $1 billion annualized U.S. revenue run rate.
- Any updates on timing and expectations for subcutaneous Briumvi Phase 3 data expected around year-end.